Evommune (EVMN) insider reports 1,000-share purchase and major indirect stakes

Rhea-AI Filing Summary

Evommune, Inc. insider and 10% owner reports a share purchase. A reporting person who is both a director and 10% owner of Evommune, Inc. (EVMN) disclosed buying 1,000 shares of common stock on 12/19/2025 at a price of $17.35 per share through a family trust.

After this transaction, 4,026 shares of common stock are reported as indirectly owned through the family trust. Additional indirect holdings are reported as 1,441,032 shares through NFLS Delta III Limited, 1,632,441 shares through Pivotal bioVenture Partners Fund I, L.P., and 294,502 shares through Pivotal bioVenture Partners Fund II, L.P. In each case, the reporting person disclaims beneficial ownership beyond their proportionate pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopfner Robert Lorne

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1841 PAGE MILL ROAD, SUITE 100

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/19/2025		P		1,000	A	$17.35	4,026	I	By Trust(1)
Common Stock								1,441,032	I	By NFLS Delta III Limited(2)
Common Stock								1,632,441	I	By Pivotal bioVenture Partners Fund I, L.P.(3)
Common Stock								294,502	I	By Pivotal bioVenture Partners Fund II, L.P.(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

2. Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

3. Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

4. Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

	/s/ Gregory S. Moss, Attorney-in-Fact	12/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Evommune (EVMN) disclose in this Form 4?

The filing reports that a director and 10% owner of Evommune, Inc. acquired 1,000 shares of common stock on 12/19/2025 at a price of $17.35 per share, held indirectly through a family trust.

How many Evommune (EVMN) shares does the insider report owning through the family trust?

Following the reported transaction, the insider reports 4,026 shares of Evommune common stock indirectly owned through a family trust, while disclaiming beneficial ownership beyond their proportionate pecuniary interest.

What indirect Evommune (EVMN) holdings are reported through NFLS Delta III Limited and related entities?

The filing reports 1,441,032 shares of Evommune common stock held by NFLS Delta III Limited, which is described as a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions for these securities are made by specified committee members, including the reporting person, who disclaims beneficial ownership beyond their pecuniary interest.

What Evommune (EVMN) shares are held through Pivotal bioVenture Partners Fund I, L.P.?

The filing lists 1,632,441 shares of Evommune common stock held by Pivotal bioVenture Partners Fund I, L.P.. Its general partner is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited, and investment and voting decisions are made by an investment committee that includes the reporting person, who again disclaims full beneficial ownership.

What Evommune (EVMN) shares are held through Pivotal bioVenture Partners Fund II, L.P.?

The document reports 294,502 shares of Evommune common stock held by Pivotal bioVenture Partners Fund II, L.P., whose general partner is also described as a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. An investment committee including the reporting person makes decisions for these holdings, with beneficial ownership disclaimed beyond the person’s pecuniary interest.

What roles does the reporting person hold at Evommune (EVMN)?

The reporting person is identified as both a Director and a 10% Owner of Evommune, Inc., and the Form 4 is filed as a single reporting person filing.